Related Experiment Video
Updated: Aug 14, 2025
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
Published on: January 7, 2019
Development and validation of novel automatable assay for cholesterol efflux capacity
Yume Mutsuda1, Tsunehiro Miyakoshi1, Yuna Horiuchi1,2,3
1Department of Analytical Laboratory Chemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Insights
A new cholesterol efflux capacity (CEC) assay using magnetic beads (ILMs) offers a simpler, automatable alternative to existing methods for predicting cardiovascular disease risk. This advancement overcomes technical hurdles, paving the way for clinical use.
Area of Science:
- Biochemistry
- Cardiovascular Disease Research
- Biomarker Development
Background:
- High-density lipoprotein (HDL) functionality is crucial for cardiovascular disease (CVD) risk prediction.
- Cholesterol efflux capacity (CEC) is a key HDL antiatherosclerotic function and a promising CVD biomarker.
- Current CEC assays face limitations, including radioactive materials and complex procedures, hindering clinical adoption.
Purpose of the Study:
- To develop a novel, simplified, and automatable cholesterol efflux capacity (CEC) assay.
- To overcome the technical limitations of existing CEC measurement methods.
- To create a more clinically applicable biomarker for cardiovascular disease risk.
Main Methods:
- Development of immobilized liposome-bound magnetic beads (ILMs) for CEC assay.
- Utilized porous magnetic beads treated with liposomes containing fluorescently labeled cholesterol.
- Validated the ILM method against the established immobilized liposome-bound gel beads (ILGs) assay.
Main Results:
- Successful immobilization of liposomes onto magnetic beads, comparable to the ILG method.
- The ILM method demonstrated sufficient basic performance and strong correlation with the ILG method.
- ILM assay showed good correlation between HDL-cholesterol levels and CEC in healthy subjects.
Conclusions:
- The novel ILM method provides a simplified and automatable approach for CEC measurement.
- This method overcomes previous technical barriers, facilitating clinical application.
- The ILM assay is a viable tool for assessing cardiovascular disease risk through HDL functionality.
Abstract:
During the past decade, evaluation of high-density lipoprotein (HDL) functionality has been well studied for predicting cardiovascular disease (CVD) risk. Cholesterol efflux capacity (CEC) is the strongest candidate as the biomarker out of various HDL antiatherosclerotic functions. However, CEC has not yet been introduced clinically because of several technical issues, including the use of radioactive materials and differentiated cells in the assay. Previously, our laboratory developed a radioisotope- and cell-free CEC assay called the immobilized liposome-bound gel beads (ILGs) method to replace the conventional method. However, the separation process of the supernatant was not suitable for installation in an automatic analyzer. The present study aims to develop a new method that is easier to operate. We assumed that the use of magnetic beads instead of gel beads would enable the skip of the centrifugal process. First, similar to the ILG method, porous magnetic beads were treated with liposomes containing fluorescently labeled cholesterol. Fluorescence was observed inside the magnetic beads, and almost the same amount of liposomes as in the ILG method was immobilized successfully. These immobilized liposome-bound magnetic beads (ILMs) were available for CEC assay when HDL and apolipoprotein B-100-depleted serum (BDS) were used as cholesterol acceptors. The ILM method showed sufficient basic performance and a good correlation with the ILG method. Furthermore, when the CEC of 15 serum samples from healthy subjects was measured, a good correlation between HDL-cholesterol level and the ILG method was confirmed. Thus, it was confirmed that the ILM method was successfully developed and could be automated.
